J
John W. Baddley
Researcher at University of Alabama at Birmingham
Publications - 170
Citations - 14088
John W. Baddley is an academic researcher from University of Alabama at Birmingham. The author has contributed to research in topics: Transplantation & Histoplasmosis. The author has an hindex of 56, co-authored 158 publications receiving 11675 citations. Previous affiliations of John W. Baddley include University Medical Center New Orleans & Oregon Health & Science University.
Papers
More filters
Journal ArticleDOI
Prospective Surveillance for Invasive Fungal Infections in Hematopoietic Stem Cell Transplant Recipients, 2001–2006: Overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database
Dimitrios P. Kontoyiennis,Kieren A. Marr,Benjamin J. Park,Barbara D. Alexander,Elias Anaissie,Thomas J. Walsh,James I. Ito,David R. Andes,John W. Baddley,Janice M. Brown,Lisa Brumble,Alison G. Freifeld,Susan Hadley,Loreen A. Herwaldt,Carol A. Kauffman,Katherine M. Knapp,G. Marshall Lyon,Vicki A. Morrison,Genovefa A. Papanicolaou,Thomas F. Patterson,Trish M. Perl,Mindy G. Schuster,Randall C. Walker,Kathleen A. Wannemuehler,John R. Wingard,Tom M. Chiller,Peter G. Pappas +26 more
TL;DR: In this national prospective surveillance study of IFIs in HSCT recipients, the cumulative incidence was highest for aspergillosis, followed by candidiasis, and understanding the epidemiologic trends and burden of IFI may lead to improved management strategies and study design.
Journal ArticleDOI
Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium
J. Peter Donnelly,Sharon C.-A. Chen,Carol A. Kauffman,William J. Steinbach,John W. Baddley,Paul E. Verweij,Cornelius J. Clancy,John R. Wingard,Shawn R. Lockhart,Andreas H. Groll,Tania C. Sorrell,Matteo Bassetti,Hamdi Akan,Barbara D. Alexander,David R. Andes,Elie Azoulay,Ralf Bialek,Robert W. Bradsher,Stéphane Bretagne,Thierry Calandra,Angela M. Caliendo,Elio Castagnola,Mario Cruciani,Manuel Cuenca-Estrella,Catherine F. Decker,Sujal R. Desai,Brian T. Fisher,Thomas S. Harrison,Claus Peter Heussel,Henrik Jeldtoft Jensen,Christopher C. Kibbler,Dimitrios P. Kontoyiannis,Bart Jan Kullberg,Katrien Lagrou,Frédéric Lamoth,Thomas Lehrnbecher,J. Loeffler,Olivier Lortholary,Johan Maertens,O. Marchetti,Kieren A. Marr,Henry Masur,Jacques F. Meis,C. Orla Morrisey,Marcio Nucci,Luis Ostrosky-Zeichner,Livio Pagano,Thomas F. Patterson,John R. Perfect,Zdenek Racil,Emmanuel Roilides,Marcus Ruhnke,Cornelia Schaefer Prokop,Shmuel Shoham,Monica A. Slavin,David A. Stevens,George Richard Thompson,Jose A. Vazquez,Claudio Viscoli,Thomas J. Walsh,Adilia Warris,L. Joseph Wheat,P. Lewis White,Theoklis E. Zaoutis,Peter G. Pappas +64 more
TL;DR: These updated definitions of IFDs should prove applicable in clinical, diagnostic, and epidemiologic research of a broader range of patients at high-risk.
Journal ArticleDOI
Clinical Practice Guidelines for the Management of Patients with Histoplasmosis: 2007 Update by the Infectious Diseases Society of America
L. Joseph Wheat,Alison G. Freifeld,Martin B. Kleiman,John W. Baddley,John W. Baddley,David S. McKinsey,James E. Loyd,Carol A. Kauffman +7 more
TL;DR: Advances in immunosuppressive treatment for inflammatory disorders have created new questions about the approach to prevention and treatment of histoplasmosis, and new information, based on publications from the period 1999-2006, are incorporated into this guideline document.
Journal ArticleDOI
Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials
David R. Andes,Nasia Safdar,John W. Baddley,Geoffrey Playford,Annette C. Reboli,John H. Rex,Jack D. Sobel,Peter G. Pappas,Bart Jan Kullberg +8 more
TL;DR: Two treatment-related factors were associated with improved survival and greater clinical success: use of an echinocandin and removal of the CVC.
Journal ArticleDOI
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial
Johan Maertens,Issam I Raad,Kieren A. Marr,Thomas F. Patterson,Dimitrios P. Kontoyiannis,Oliver A. Cornely,Eric J. Bow,Galia Rahav,Dionysios Neofytos,Mickael Aoun,John W. Baddley,Michael Giladi,Werner J. Heinz,Raoul Herbrecht,William W. Hope,Meinolf Karthaus,Dong-Gun Lee,Olivier Lortholary,Vicki A. Morrison,Ilana Oren,Dominik Selleslag,Shmuel Shoham,George Richard Thompson,Misun Lee,Rochelle Maher,Anne Schmitt-Hoffmann,Bernhardt Zeiher,Andrew J. Ullmann +27 more
TL;DR: The results support the use of isavuconazole for the primary treatment of patients with invasive mould disease and non-inferiority was shown.